卒中中的肠道菌群及其代谢物:一把双刃剑
本综述总结肠道菌群、微生物组及其代谢物在实验性与临床卒中的作用,并探讨其作为治疗靶点的潜力。14项临床研究在卒中与健康对照间共识别出62个上调菌属(如链球菌属、乳杆菌属、埃希菌属)和29个下调菌属(如真杆菌属、罗斯氏菌属),多数研究显示卒中患者肠道微生物组多样性降低。
要点
- 卒中与肠道菌群失调互为因果,菌群可影响卒中发生、预后与恢复。
- 14项临床研究识别出卒中相关上调菌属62个、下调菌属29个。
- 多数研究显示卒中患者肠道微生物组多样性降低。
核心结论
- 肠道菌群及其代谢物在实验性与临床卒中中可能发挥双向作用,靶向肠道菌群代谢物的临床干预有望成为卒中防治的新方向。
研究设计与样本
- 本综述总结肠道菌群、微生物组及菌群代谢物在实验性与临床卒中的作用及其潜在治疗靶点价值。
主要发现
- 14项临床研究在卒中与健康参与者之间识别出62个上调菌属(如链球菌属、乳杆菌属、埃希菌属)和29个下调菌属(如真杆菌属、罗斯氏菌属);多数研究显示卒中患者肠道微生物组多样性降低。
- 实验性卒中中,卒中严重程度取决于肠道微生物组组成,而后者可随抗生素、年龄和饮食发生较大变化;非细菌微生物尚待研究。
- 摄入富含胆碱和左卡尼汀的食物通过产生氧化三甲胺与实验性和临床卒中的发生呈正相关;小鼠中摄入膳食纤维可改善卒中结局,可能通过短链脂肪酸(如乙酸盐、丙酸盐、丁酸盐)介导。
临床怎么用
- 作者认为,针对肠道菌群代谢物的临床干预作为卒中预防和治疗的新机会值得开展。
局限性
- 多数证据来自实验性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Besides damaging the brain, stroke causes systemic changes, including to the gastrointestinal system. A growing body of evidence supports the role of the gut and its microbiota in stroke, stroke prognosis, and recovery. The gut microbiota can increase the risk of a cerebrovascular event, playing a role in the onset of stroke. Conversely, stroke can induce dysbiosis of the gut microbiota and epithelial barrier integrity. This has been proposed as a contributor to systemic infections. In this review, we describe the role of the gut microbiota, microbiome and microbiota-derived metabolites in experimental and clinical stroke, and their potential use as therapeutic targets. Fourteen clinical studies have identified 62 upregulated (eg, Streptococcus, Lactobacillus, Escherichia) and 29 downregulated microbial taxa (eg, Eubacterium, Roseburia) between stroke and healthy participants. The majority found that stroke patients have reduced gut microbiome diversity. However, other nonbacterial microorganisms are yet to be studied. In experimental stroke, severity is dependent on gut microbiome composition, whereas the latter can greatly change with antibiotics, age, and diet. Consumption of foods rich in choline and L-carnitine are positively associated with stroke onset via production of trimethylamine N-oxide in experimental and clinical stroke. Conversely, in mice, consumption of dietary fiber improves stroke outcome, likely via gut microbiota-derived metabolites called short-chain fatty acids, such as acetate, propionate, and butyrate. The majority of the evidence, however, comes from experimental studies. Clinical interventions targeted at gut microbiota-derived metabolites as new therapeutic opportunities for stroke prevention and treatment are warranted.
引用
- Peh A, O'Donnell JA, Broughton BRS, et al. Gut Microbiota and Their Metabolites in Stroke: A Double-Edged Sword. Stroke. 2022. PMID: 35135325. doi:10.1161/STROKEAHA.121.036800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。